简体中文
Français
Deutsch
日本語
Español
Labcorp
Careers
Investigators
Order a Kit
Trial Share
Clinical Trials
Choose Language
Solutions
Solutions
Back
Development
Development
Back
By Phase
By Phase
Back
Phase IV & RWE
By Scientific Discipline
By Therapeutic
By Therapeutic
Back
Cardiovascular
Dermatology
Diabetes and Endocrinology
Inflammation
NASH
Neuroscience & CNS
Rare & Orphan
Ophthalmology
Pediatrics
Infectious Disease
Nephrology
By Region
By Region
Back
Asia Pacific
By Molecule or Product
By Molecule or Product
Back
Biologic Drug Development & Testing
Small Molecule
Biosimilars Development Solutions
Cell and Gene Therapy Solutions
RD Healthcare
RD Healthcare
Back
Commercialization
Oncology
Oncology
Back
Preclinical
Preclinical
Back
Model & tech spotlights
Tumor models
ACT & CAR T
In vitro
Posters
Fast Track Discovery
Clinical trials
Clinical trials
Back
Consulting team
Patient Recruitment
Immunotherapy
Immunotherapy
Back
Preclinical
Clinical
Education
Education
Back
Top 5 Models for Immuno-oncology Studies
Top 5 Design Considerations for Preclinical Immuno-oncology
Events
Contact
Lung & Respiratory
Lung & Respiratory
Back
In vivo/vitro models
Respiratory trials
Inhalation
Device
Education
Services
Services
Back
Analysis
Analysis
Back
Bioanalytical
Bioanalytical
Back
LC-MS Immunoanalytical
Specialty LC-MS
Discovery BioA
Vaccine Analysis
Methods
Education
DMPK
DMPK
Back
In Vitro Metabolism
In Vivo Metabolism
MetID
Modeling & In Silico
Custom Antibody Reagents
Custom Antibody Reagents
Back
Reagent Portfolio Management Solution
Critical Antibody Reagents
Tool Reagents
Polyclonal Antibody Services
Monoclonal Antibody Production
Antibody Reagent Scientific Spotlights
Discovery & LO
Discovery & LO
Back
Non-GLP Safety
Non-GLP Safety
Back
Core Lead Optimization Toxicology Services
Safety Assessment
Disease Models
Disease Models
Back
Comprehensive Leukocyte Quantitation
RD Oncology Cell Line Assays
PK/TK
Nonclinical Imaging
Nonclinical Imaging
Back
Computed Tomography
Bioluminescence
Analysis
Positron Emission
Radiation
Flow Cytometry
Vaccines
Pathology
Pathology
Back
Anatomic pathology
Clinical pathology
Specialty pathology
Specialty pathology
Back
Electron microscopy
Immunohistochemistry
Tissue cross reactivity
Digital pathology
CMC Analytical
CMC Analytical
Back
Assessments
Lifecycle development
Project management
Formulation
Analytical
Education
Toxicology
Toxicology
Back
General
General
Back
Core services
Abuse liability
Infusion
Juvenile
Neurotoxicity
NHP
Ocular
SEND 3.1
Genetic
Genetic
Back
Regulatory
Screening
Multi-endpoint
Immunotoxicology
Immunotoxicology
Back
Therapeutic immunology
Immunotoxicology testing
Technology, platforms and assays
Scientific expertise
Regulatory
Pharmacology
Pharmacology
Back
Cardiovascular (in vitro & vivo)
ICH Core Battery
ICH Supplemental
Discovery Support
Neurotoxicology
Infusion
Drug Abuse Assessment Education Center
DART
DART
Back
SEG I
SEG II
SEG III
ePPND
Juvenile
Specialty Techniques
Infusion
SEND 3.1
SEND 3.1
Back
SEND Education Center
Administration routes
Administration routes
Back
Inhalation
Consulting
Consulting
Back
Drug Development Consulting
Clinical Development
Clinical Development
Back
Clinical pharmacology
Clinical pharmacology
Back
Education
Discover the New Leeds Clinic
Early clinical
Early clinical
Back
Early Patient
Trial Management
Adaptive Trials
CRU Virtual Tours
Patient Recruitment
Late clinical
Late clinical
Back
CTMS
Optimization Software
Patient Safety & PV
Phase IV & RWE
Data analysis & reporting
Global compliance
Global compliance
Back
Strategy
Compliance & QA
Global Submissions
Medical Writing
Japan
CRU virtual tours
Decentralized Clinical Trials
Decentralized Clinical Trials
Back
Mobile Clinical Services
snapClinical® Platform
Patient Service Centers
PoC studies
Clinical Testing & Labs
Clinical Testing & Labs
Back
Central labs
Central labs
Back
Core Services
Kits & Logistics
Specimen Management
GlobalCODE
Resources
Lab Data
Precision Medicine
Precision Medicine
Back
Biomarkers
Biomarker Solution Center
Companion Diagnostics (CDx)
Genomics
Cell and Gene Therapies
Immuno-Oncology
Specialty testing
Specialty testing
Back
Translational Biomarkers
Flow Cytometry
Expanded Lab Management
Vaccines & Immunology
Pathology & Histology
Functional Service Provider (FSPx)
Functional Service Provider (FSPx)
Back
Education
Nonclinical
Nonclinical
Back
Early Phase Development
IND & CTA Enabling Studies
Nonclinical Locations
Nonclinical Locations
Back
Ann Arbor
Harrogate
Madison
Shanghai
San Carlos
SEND 3.1
SEND 3.1
Back
Educational Resources
Peri-approval & commercialization
Peri-approval & commercialization
Back
Commercialization
Commercialization
Back
Evidence generation
Field services
Market access consulting
Economic modeling
Pricing
Value communication
Access: Australia & Asia-Pacific
Patient Access Solutions
Patient Access Solutions
Back
Assistance programs
Clinical services
Affordability
Pharmacy
Adherence
PV & Patient Safety
PV & Patient Safety
Back
Aggregate reporting
Automation
Safety consulting
Pharmacovigilance (PV)
Safety Technology
Detection & risk management
Education
Phase IV
Data and Technology
MarketPlace
Clients
Clients
Back
Pharma Companies
Biopharmaceutical
Biopharmaceutical
Back
Partner
Approach
Value
Transition
Contact
Investigators
Investigators
Back
Order a Kit
Become an Investigator
Accreditations and Certifications
Current Investigator Resources
Current Investigator Resources
Back
Courier Numbers
Label: UPS Express Critical
Order: Dry Ice
Privacy Statement: Institution
Privacy Statement: Investigator
Privacy Statement: Study Staff
Videos: Packing & Shipping
Videos: Sample Collection
FAQs
Participate in a Trial
Device / Diagnostics
Device / Diagnostics
Back
Education Center
Life Science Investor Solutions
Articles & Research
Articles & Research
Back
Blog
Knowledge Library
Knowledge Library
Back
KL Detail
KL Search Page Custom
Secure PDF Viewer
PDF Viewer
About
About
Back
About Us
Animal Welfare
Animal Welfare
Back
Why Animal Research
Impact on Results
Beliefs in Action
Corporate Responsibility
Contact
Contact
Back
Thank You
Thank You
Labcorp
Careers
Investigators
Order a Kit
Trial Share
Clinical Trials
<
Solutions
Services
Clients
Articles & Research
About
Contact
>
By Therapeutic or Specialty Area
Cardiovascular
Dermatology
Diabetes and Endocrinology
Immuno-Oncology
Infectious Diseases
Inflammation
Nephrology
Neuroscience
Non-Alcoholic Steatohepatitis (NASH)
Oncology
Rare Disease and Orphan Drugs
Ophthalmology
Pediatrics
Respiratory & Pulmonary
By Phase
Preclinical
Phase I-IIa
Phase IIb-III
Phase IV-RWE
Clinical pharmacology
By Geography
By Molecule or Product Type
Biologics Solutions
Biomarkers
Small Molecule Solutions
Biosimilars Development Solutions
Cell & Gene Therapy Solutions
Data & Technology Solutions
Design Better Studies
Improve Study Recruitment
Reduce Study Risk
Gain Operational Insights
Ensure Data Quality
Access Central Laboratory Information
Empower Your Data
Maximize Product Access
Transform Patient Safety
Device & Diagnostics
Functional Service Provider (FSP)
Commercialization
Market Access and Phase IV Solutions
Analysis
Bioanalytical
DMPK
Custom Antibody Reagents
Discovery & LO
Non-GLP Safety
Disease Models
PK/TK
Nonclinical Imaging
Radiation
Flow Cytometry
Vaccines
Pathology
Anatomic pathology
Clinical pathology
Specialty pathology
CMC Analytical
Assessments
Lifecycle development
Project management
Formulation
Analytical
Education
Toxicology
General
Genetic
Immunotoxicology
Pharmacology
DART
SEND 3.1
Administration routes
Inhalation
Consulting
Drug Development Consulting
Clinical Development
Clinical pharmacology
Early clinical
Late clinical
Phase IV & RWE
Data analysis & reporting
Global compliance
CRU virtual tours
Decentralized Clinical Trials
PoC studies
Clinical Testing & Labs
Central labs
Precision Medicine
Specialty testing
Functional Service Provider (FSPx)
Education
Nonclinical
Early Phase Development
IND & CTA Enabling Studies
Nonclinical Locations
SEND 3.1
Peri-approval & commercialization
Commercialization
Patient Access Solutions
PV & Patient Safety
Phase IV
Data and Technology
MarketPlace
Pharma Companies
Biopharmaceutical
Investigators
Participate in a Trial
Device / Diagnostics
Life Science Investor Solutions
Our Company
About Us
Blog
Our Values
Corporate Responsibility
Animal Welfare
Resource Centers
Bioanalysis
Biopharm CMC
Biosimilars
Clinical Pharmacology
Functional Service Provider (FSPx)
Immuno-Oncology
Infectious Diseases
Inflammation
Oncology
Patient Safety
NASH Solutions
Rare Disease and Orphan Drugs
SEND
Vaccines
Contact Us
Contact Us Form
Clinical Trials
Participate in a Clinical Trial
+1.888.268.2623 (The Americas)
+1.609.452.4440
+00.800.2682.2682 (Europe/Africa)
+44.1423.500888
+800.6568.3000 (Asia/Pacific)
+65.6.5686588 (Asia/Pacific local)
Global Office Locations
Connect With Us
Media Relations
Request an Interview
Request a Speaker
Investigators
Kit Ordering
Investors
Investor Relations
Job Seekers
Careers
Home
Covance Sitemap
Covance Sitemap
Sitemap List
Solutions
Development
By Phase
Research
Preclinical
Locations
Shanghai
Ann Arbor
Harrogate
Madison
San Carlos
Clinical (Phase I - III)
Programmatic Solutions
Molecule Development Group
Phase IV & RWE
By Scientific Discipline
By Therapeutic
Cardiovascular
Dermatology
Diabetes and Endocrinology
Inflammation
Inflammation Education Center
Rheumatoid Arthritis
Respiratory Drug Development Solutions
NASH
Education
Neuroscience & CNS
Oncology
Immuno-Oncology
Immuno-Oncology Education Center
Oncology Education Center
Preclinical
Rare & Orphan
Rare Diseases Drug Development Solutions and Clinical Trials
Education
Ophthalmology
Pediatrics
Infectious Disease
Education
Nephrology
By Region
Asia Pacific
Australia
China
Hong Kong
India
Japan
Korea
Malaysia
New Zealand
Philippines
Singapore
Taiwan
Thailand
APAC Education Center
By Molecule or Product
Biologic Drug Development & Testing
Small Molecule
Biosimilars Development Solutions
Education
Cell and Gene Therapy Solutions
RD Healthcare
Commercialization
Patient and Provider Services
Patient Assistance Programs (PAP)
Patient Access Programs 2020 Events
Patient Assistance
Pharmacy Services
Healthcare Technology
Patient Access Programs 2020 Events
Market Access Consulting
Managed Markets Services
Oncology
Preclinical Oncology CRO | Labcorp Drug Development
Model & tech spotlights
4T1-luc2: An orthotopic mammary cancer odel to support novel immuno-oncology drug discovery
5TGM1-luc – A syngeneic murine model for multiple myeloma
786-O (pMMP-LucNeo) – A model for renal cell carcinoma
A20: Modeling B cell lymphoma in mice
Absolute counts by flow cytometry — maximize the accuracy of your immunophenotypic data interpretation
A deeper dive into the tumor-infiltrating T Cell immunophenotype
B16-F10: a murine melanoma model
5TGM1-luc – A syngeneic murine model for multiple myeloma
A549 – A model for non-small cell lung cancer
zPREDICTA®’s Reconstructed Bone (r-Bone)
Syngeneic model for preclinical evaluation of ovarian cancer
Comprehensive dendritic cell analysis by flow cytometry using the new CompDC™ panel
Modeling human acute lymphoblastic leukemia (ALL) – using the NALM6-Luc-mCh-Puro model for the development of CAR T cell therapies
C1498: A murine model for acute myelogenous leukemia (AML)
Colo-205 as a translational imaging model for colorectal cancer
Pan02: A murine model of pancreatic cancer
Hepa 1-6: A murine model of hepatocellular carcinoma
CT26: Murine colon carcinoma
Modeling liver cancer with syngeneic hepa 1-6: an update
Models for non-small cell lung carcinoma
MM.1S: A model for multiple myeloma
ID8 syngeneic ovarian cancer model response to checkpoint inhibitors
Targeting B Cell malignancies? Raji-Luc is a model to test CD19-directed CAR-T cells and other novel approaches
PyMT – a transplantable murine model of breast cancer
Update on the preclinical use of hPBMC for immuno-oncology modeling
Focal radiation in the murine 4T1-luc2 mammary cancer model
Subcutaneous and systemic preclinical modeling of A20 murine B cell lymphoma
Pan02 – pancreatic ductal adenocarcinoma model characterized for immuno-oncology applications
Measuring Tumor Antigen-Specific Immunity Through ELISpot and FluoroSpot
Functional analysis of tumor infiltrating lymphocytes by flow cytometry using the cytokine/cytotoxicity™ panel
MDA-MB-231-luc-D3H2LN: A valuable model for triple-negative breast cancer research
MV(4;11): A model of human AML (acute myeloid leukemia)
Phospho-protein detection in solid tumors using phospho-flow cytometry
MC38: An immunoresponsive murine tumor model
Prostate cancer modeling with PC-3: One model, four applications
MB49 – a bladder cancer murine tumor model
E0771 syngeneic breast cancer model
EMT-6 syngeneic breast tumor model – a powerful tool for immuno-oncology studies
HCC70: A model of triple negative breast cancer
HT-29 as a preclinical model for colorectal cancer
Models for pancreatic cancer
ID8: A syngeneic mouse model for testing ovarian cancer immunotherapies
C1498-Luc-mCherry: A syngeneic acute myeloid leukemia (AML) model
GL261: Syngeneic murine glioma model
Models for non-small cell lung carcinoma - part 2
LL/2: an immunosuppressive murine tumor model
NCI-H2228 – usage of DCE MRI in a non-small cell lung cancer orthotopic brain metastatis model
BT-474 Human ductal breast carcinoma: New life for an old model
GL261-luc: A model for immunotherapy and radiation therapy
PC-3M-Luc-C6 – a model for prostate carcinoma
Modeling immuno-oncology in a humanized mouse
Multiplex IHC for patterns of protein expression, co-expression, and spatial relationships
NCI-1975-Luc and PC-9-Luc: two models for evaluating brain metastases from non-small cell lung cancer It is missing the “H” NCI-H1975-Luc and PC-9-Luc: two models for evaluating brain metastases from non-small cell lung cancer
Preclinical oncology imaging capabilities and expertise
Analysis of the tumor-infiltrating myeloid subsets with high dimensional flow cytometry using the Expanded CompMyeloid™ panel
Measuring human cytokines in mouse samples in the discovery setting: Understanding immunoassay technology and managing the risk
Combination therapies in oncology: The future of CAR T cell therapy for solid tumors
Determining preclinical CAR T-cell persistence by flow cytometry
Cloudman S91 – a responsive syngeneic melanoma model
Labcorp chimeric antigen receptor (CAR) T cell generation service
Luciferase-labeled cell lines: a valuable tool for oncology studies
Clinical standards of care in preclinical models of multiple myeloma
Pan02-Luc: An orthotopic model of pancreatic cancer
CT26-Luc: An orthotopic murine model of colon cancer: implications for immuno-oncology studies
EMT6-Luc: In vivo monitoring of metastatic development and treatment efficacy
Bioluminescence imaging: In vivo monitoring of tumor development, disease dissemination and treatment efficacy
Labcorp Drug Development Preclinical Oncology Biosafety Level 2 Capabilities and Ongoing Expansion
RM-1: A Syngeneic Murine Prostate Gland Carcinoma Model
Raising the Bar in Preclinical Oncology
The nCounter® IO 360™ panel and flow cytometry combine transcriptome and immune subset immunophenotypic profiles to offer comprehensive analysis of tumor immunotherapy
NHDF (normal human dermal fibroblasts)
NCI-H929-Luc-mCh-Puro Human Multiple Myeloma
Reh (pMMP-Luc-Neo) Human B Cell (Acute Lymphocytic) Leukemia
SK-OV-3 (SUBCUTANEOUS)
OVCAR-8-Luc-mCh-Puro
NCI-H1975-LUC
NCI-H1703-LUC-MCH-PURO
NCI-H1703
NCI-H125-LUC
NCI-H125
NAMALWA
MV-4-11-Luc-mCh-Puro: Human Acute Meylogenous Leukemia
MV-4-11
MOLT-4-LUC-MCH-PURO
MOLT-4
MMTV-PYMT
MIA PACA-2-LUC
MDA-MB-453
MDA-MB-435S
MDA-MB-361
LOVO-6-LUC1
LN-18
HCT-15
NIH:OVCAR-3-LUC-MCH-PURO
Pfeiffer
Renca
HepG2
786-O-LUC-NEO
E.G7-OVA: Murine Thymic Lymphoma
NHDF (normal human dermal fibroblasts)
OVCAR-4
OVCAR-5: Human Ovarian Carcinoma
NCI-H446
NCI-H3122: Human Lung Adenocarcinoma
NCI-H929-Luc-mCh-Puro Human Multiple Myeloma
RAMOS-LUC
PANC-1-LUC
Pan02: Murine pancreatic ductal adenocarcinoma
OVCAR-8: Human Ovarian Carcinoma
NCI-H460 Human Lung Carcinoma
TMD8
UACC-62
U-87 MG-Luc: Human glioblastoma
SW-480: Human Colon Carcinoma
SW-620: Human Colon Carcinoma
NCI-H295R
SF-539
SU-DHL-10 Human Large Cell Lymphoma
NCI-N87: Human Gastric Carcinoma
Reh (pMMP-Luc-Neo) Human B Cell (Acute Lymphocytic) Leukemia
Raji-luc: Human B-Cell Lymphoma
Ramos: Human B-cell Lymphoma
U-251-luc-mCh-Puro: Human Glioblastoma
SNU-5 Human Gastric Carcinoma
RIF-1: Mouse Sarcoma
SJSA-1 Human Osteosarcoma
PC-3M-Luc-C6 (SC-axilla)
PC-3M-Luc-C6 (Peritibial)
PC-3M-Luc-C6 (Orthotopic)
PC-3M-Luc-C6 (Intracardiac)
PC-3
PANC-1: Human Pancreatic Carcinoma
SK-OV-3-LUC-D3 (INTRAPERITONEAL)
SK-OV-3 (SUBCUTANEOUS)
OVCAR-8-Luc-mCh-Puro
Neuro-2a
RPMI 8226
YUMM1.7: Murine Melanoma
SK-MEL-28
ZR-75-1: Human Mammary Carcinoma (w/estradiol)
UISO-BCA-1
PC-9
NCI-H292
THP-1
NCI-H322M
NCI-H441
NCI-H460-LUC2
NCI-H508
NCI-H522
NCI-H23: Human Non-Small Cell Lung Carcinoma
NCI-H2122
NCI-H2110
NCI-H1975-LUC
NCI-H1975 Human Non-Small Cell Lung Carcinoma
NCI-H1703-LUC-MCH-PURO
NCI-H1703
NCI-H1650
NCI-H1299
NCI-H125-LUC
NCI-H125
NAMALWA
NALM6-Luc: Adult B Acute Lymphoblastic Leukemia
NALM6
MX-1-LUC
MX-1: Human Mammary Carcinoma
MV-4-11-Luc-mCh-Puro: Human Acute Meylogenous Leukemia
MV-4-11
MOLT-4-LUC-MCH-PURO
MOLT-4
MOLM-13
MMTV-PYMT
MM.1S (pMMP-Luc-Neo): Human Plasma Cell Myeloma
MKL-1
MIA PACA-2-LUC
MIA PaCa-2: Human Pancreatic Ductal Adenocarcinoma
MG-63
MDA-MB-468
MDA-MB-453
MDA-MB-435S
MDA-MB-361
MDA-MB-231-LUC-D3H3
MDA-MB-231-Luc-D3H2LN: Human Mammary Carcinoma
MDA-MB-231-LUC-D3H2
MDA-MB-231-LUC-D3H1
MDA-MB-231-2LMP
MDA-MB-231: Human Mammary Carcinoma
MCF7-LUC-MCH-PURO
MCF 10A
MCF-7
MC38: Murine Colon Adenocarcinoma
MBT-2
MB49-LUC-MCH-PURO
MB 49: Murine Bladder Cell Carcinoma
MB-1
M14
M059K
M-NFS-60
LS411N
LS 174T
LOX-IMVI: Human Melanoma
LOVO-6-LUC1
LOVO
LNCAP CLONE FGC
LN-229
LN-18
LN-827 (PMMP-LucNeo): Human Glioma
LL/2-LUC-M38
LL/2
Lewis Lung: Mouse Lung Carcinoma
L1210
KP4: Human Pancreatic Ductal Carcinoma
Kg-1-Luc-mCh-Puro: Human Leukemia (AML)
KB
Kasumi-3-Luc-mCh-Puro: Human Leukemia (AML)
Kasumi-3
Kasumi-1 Human Acute Myeloblastic Leukemia
KARPAS 299
K-562-LUC2
K-562
Jurkat-Clone E6-1
Jurkat: Human Lymphoblastic Leukemia
JJN-3-LUC-G418R
J82
J774A.1
J558-Luc-mCh-Puro
IGROV1: Human Ovarian Carcinoma
ID8-Luc: Murine Ovarian Carcinoma
ID8
HUT 78
HT-29-LUC
HT-29: Human Colon Carcinoma
HT-1376
HT-1080
HT
HS 895.T
HS 895.SK
HS 578T
HS 578BST
HL-60
HEPA 1-6-LUC-MCH-PURO
Hepa 1-6
HEP G2
Hep-55.1C-Luc-Mch-Puro
Hep-55.1C
Hep 3B2.1-7: Human Hepatocellular Carcinoma (HCC)
HELA
Hel-Luc-Neo
Hel 92.1.7-Luc-Neo
Hel 92.1.7
Hel
HEKN (Human Epithelial Keratinocytes)
Hek 293-Luc-mCh-Puro
Hek 293
HCT-8
HCT-15
HCT-116-LUC
HCT-116: Human Colon Carcinoma
HCC827-LUC-MCH-PURO
HCC827
HCC70: Human Triple Negative Mammary Carcinoma
HCC2998
HCC1395
GRANTA-519
GLI36-DSRED-R-LUC (RESCUED)
GL261-Luc2: Mouse Glioma
GL261
GIST-T1: Human Gastrointestinal Stromal Tumor
G-361
FARAGE
FaDu: Human Pharyngeal Squamous Cell Carcinoma
EOL-1
EMT-6 Murine Mammary Carcinoma
EBC-1
E0771: Murine Mammary Carcinoma
DU 145-LUC
DU 145: Human Prostate Carcinoma
DND-41-LUC-MCH-PURO
DMS 114
DLD-1: Human Colon Carcinoma
DBTRG (TUMOR)
DBTRG-05MG
DB/M2
DB
Daudi-luc-mCh-Puro: Human B-Cell Lymphoma
DAUDI
D54-Luc: Human Glioma
CWR-22-R
CT26.WT: Murine Colon Carcinoma
COS-7
COLO 829: Human Melanoma
COLO 205-LUC #2
COLO 205: Human Colon Carcinoma
CCRF-CEM
CAPAN-2
CAPAN-1
Calu-6: Human Lung Adenocarcinoma
CALU-3
CALU-1
CAL 27: Human Tongue Squamous Cell Carcinoma
CAKI-1
CACO-2
C51: Mouse Colon Carcinoma
C2BBE1
C26: Mouse Colon Carcinoma
C1498-Luc: Murine Leukemia
C1498
BXPC-3-LUC2
Bx-PC-3: Human Pancreatic Carcinoma
BT142: Human Oligoastrocytoma (Glioma)
BT-474: Human Mammary Invasive Ductal Carcinoma
BT-20
BNL 1ME A.7R.1-LUC-MCH-PURO
BNL 1ME A.7R.1
BEWO
B16-F10-Luc2: Murine Melanoma
B16-F10-LUC-G5
B16-F10: Murine Melanoma
B-JAB
ARH-77
ACHN Human Renal Carcinoma
AB1-LUC-MCH-PURO
AB1
A549-LUC-C8
A549: Human Lung Carcinoma
A375: Human Melanoma
A2780-LUC
A2780
A2058
A20-LUC2-PURO
A20 Murine B Cell Lymphoma
A-673
A-498 Human Renal Carcinoma
A-431
786-O
769-P
5TGM1-Luc: Murine Multiple Myeloma
4T1-LUC2: Mouse Mammary Carcinoma
22RV1
P388D1-Luc
NCI-H596
NCI-H69
NCI-H82
NCI-H929
NIH:OVCAR-3
NIH:OVCAR-3-LUC-MCH-PURO
NK-92MI
NOMO-1
NUGC-4
OCI-LY1 LN
OCI-LY19-LUC-NEO
OCI-LY3-LUC-MCH-PURO
OCI-LY7-LUC-MCH-PURO (RESCUED)
OCI-LY7-LUC-NEO
OCM-1
OCM-1-LUC-MCH-PURO
OE33
OPM-2
OV-90
OVCAR-5-LUC-MCH-PURO
P388
P815
PA-NUT
PAN02.TD1-LUC-MCH-PURO
PC-3-LUC
PAN03
Syngeneic Cancer Cell Lines and Growth Curves
Human Cancer Cell Lines and Growth Curves
OVCAR-3 (PMMP-LUC-NEO): Human ovarian carcinoma – Intra-bursa
OVCAR-3 (PMMP-LUC-NEO): Human ovarian carcinoma – IP
SW 1990
NCI-H1299-Luc: Human Large Cell Lung Carcinoma
Pfeiffer
B16
Raji
Raw-264-7
Reh
Renca
RL
SF-295
Saos-2
SF-767
SHP-77
SK-BR-3
SK-LMS-1
SK-MEL-28-Luc-mCh-Puro
SK-MEL-5
SK-MES-1
SK-N-AS
SK-N-FI
SK-N-SH
SNB-19
SU-86.86
SU-DHL-10-LN-HIGH
SU-DHL-16
SU-DHL-4-LUC-MCH-PURO
SU-DHL-6
SU-DHL-6-LUC-MCH-PURO
SU-DHL-8
SW 872
T24
T24-LUC-NEO
T24P
T47D
TE 353.SK
TK-10
TOLEDO-LUC-NEO
U-251
U266B1
WM-115
WSU-DLCL2
WSU-FSCCL
YAC-1
TF-1A-LUC-NEO
WALKER256
5637
HepG2
Tumor models
Subcutaneous Models
Orthotopic Models
Metastasis Models
Disseminated Models
ACT & CAR T
In vitro
Immunohistochemistry
Protein expression
DNA/RNA expression
Cell processes
Cell & tissue processing
Cell culture
Blood/plasma analysis
Posters
A comparative evaluation of immunotherapy responses in murine colon carcinoma
Anti-mCTLA-4 treatment results in early and late immune response effects in a murine model of colorectal carcinoma
Characterization of proliferation in multiple lymphocyte subsets in the CT26 murine colon carcinoma model by multi-color flow cytometry
Combination of a glycomimetic antagonist to E-selectin and CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates regulatory T Cell infiltration and accelerates time to complete response in the murine CT26 tumor model
Combination of rapamycin with immune checkpoint blockade in a syngeneic breast carcinoma model
Combined dynamic 18F-FDG PET imaging and DCE prediction of treatment response in an orthotopic model of glioblastoma multiforme
Combined focal radiation and anti-mCTLA-4 antibody therapy modulates myeloid subset phospho-stat3 levels in the 4T1 tumor microenvironment, and results in tumor growth inhibition
Comprehensive 10-color flow cytometry analysis of the neuroblastoma intratumoral immune response using the murine syngeneic Neuro-2a tumor model
Evaluation of the immune response following treatment with anti‐CTLA‐4 antibody, radiation therapy or the combination in a murine model of breast cancer
Evaluation of immunomodulatory agents in classically immunologically “cold” cancers using syngeneic mouse models of breast and ovarian cancer
Focal radiation enhances paclitaxel therapy in a mouse model of triple negative breast cancer
High-throughput analysis of MAPK and JAK-STAT signaling in CT26 tumors using a combination of immunophenotyping and phospho-flow cytometry
ID8-Luc syngeneic ovarian cancer model for preclinical evaluation of immunomodulatory molecules
Image-guided focal irradiation in syngeneic preclinical oncology mouse models
Imaging the future | Published in the European Biopharmaceutical Review
In-depth myeloid cell characterization in the murine syngeneic CT.26 colon carcinoma model by 10-color flow cytometry
Preclinical assessment of anti-tumor activity and immune response in syngeneic tumor models
Preclinical models of multiple myeloma
Preclinical response of murine syngeneic tumor models to immune checkpoint inhibitor antibodies
Preclinical use of focal radiation and immune checkpoint blockade to improve therapeutic response in an immunologically cold tumor
Radiation enhances anti-tumor activity of checkpoint blockade in syngeneic tumor models
Radiation response in preclinical orthotopic models of brain cancer
Sensitivity of syngeneic tumor models to focal radiation
Systemic and subcutaneous modeling of A20 murine B cell lymphoma in mice: A comparative assessment
TIGIT directed human antibody modulates T-regulatory and effector cell function
Fast Track Discovery
Clinical trials
Consulting team
Patient Recruitment
Immunotherapy
Preclinical
Clinical
Education
Top 5 Models for Immuno-oncology Studies
Top 5 Design Considerations for Preclinical Immuno-oncology
Events
Contact
Lung & Respiratory
In vivo/vitro models
Respiratory trials
Inhalation
Device
Education
Services
Analysis
Bioanalytical
LC-MS Immunoanalytical
Development & Validation
Sample Analysis
Immunoanalytical
Microfluids
Specialty LC-MS
Targeted Proteomics
Discovery BioA
Vaccine Analysis
Methods
Education
DMPK
In Vitro Metabolism
Enzyme Induction
Enzyme Inhibition
Metabolic Stability
Metabolism Protein Binding Studies & Services | Covance Preclinical
Reaction Phenotyping
Transporters & DDIs
In Vivo Metabolism
MetID
Human AME
Modeling & In Silico
Compartmental PK
PK / PD Modeling
PBPK Modeling
QSP / SP Modeling
Custom Antibody Reagents
Reagent Portfolio Management Solution
Critical Antibody Reagents
Tool Reagents
Polyclonal Antibody Services
Monoclonal Antibody Production
Antibody Reagent Scientific Spotlights
Discovery & LO
Non-GLP Safety
Core Lead Optimization Toxicology Services
Safety Assessment
Disease Models
Comprehensive Leukocyte Quantitation
RD Oncology Cell Line Assays
PK/TK
Nonclinical Imaging
Computed Tomography
Bioluminescence
Analysis
Positron Emission
Radiation
Flow Cytometry
Vaccines
Custom Antibody Reagents
Toxicologic Pathology CRO Services
Anatomic pathology
Clinical pathology
Specialty pathology
Electron microscopy
Immunohistochemistry
Tissue cross reactivity
Digital pathology
CMC Analytical
Assessments
Lifecycle development
Project management
Formulation
Analytical
Education
Toxicology
General
Core services
Abuse liability
Infusion
Juvenile
Neurotoxicity
NHP
Ocular
SEND 3.1
Genetic
Regulatory
Screening
Multi-endpoint
Immunotoxicology
Therapeutic immunology
Immunotoxicology testing
Technology, platforms and assays
Scientific expertise
Regulatory
Pharmacology
Cardiovascular (in vitro & vivo)
ICH Core Battery
ICH Supplemental
Discovery Support
Neurotoxicology
Infusion
Drug Abuse Assessment Education Center
DART
SEG I
SEG II
SEG III
ePPND
Juvenile
Specialty Techniques
Infusion
SEND 3.1
RD - SEND Education Center
Administration routes
Inhalation
Consulting
Drug Development Consulting
GlobalCODE® Specimen Tracking
Clinical Development
Clinical pharmacology
Education
Discover the New Leeds Clinic
Early clinical
Early Patient
Trial Management
Adaptive Trials
CRU Virtual Tours
Patient Recruitment
Late clinical
CTMS
Optimization Software
Patient Safety & PV
Phase IV & RWE
Data analysis & reporting
Global compliance
Strategy
Compliance & QA
Global Submissions
Medical Writing
Japan
CRU virtual tours
Decentralized Clinical Trials
Mobile Clinical Services
snapClinical® Platform
Patient Service Centers
PoC studies
Clinical Testing & Labs
Central labs
Core Services
Kits & Logistics
Specimen Management
GlobalCODE
Resources
Asia & Pacific
Europe, Middle East & Africa
Latin America
United States, Canada & Puerto Rico
Lab Data
Precision Medicine
Biomarkers
Biomarker Solution Center
Companion Diagnostics (CDx)
Genomics
Cell and Gene Therapies
Cell and Gene Therapy Expert Teams
Cell Therapies
Gene Therapies
Education
Immuno-Oncology
Specialty testing
Translational Biomarkers
Flow Cytometry
Expanded Lab Management
Vaccines & Immunology
Assays to Support Vaccines and Novel Immunotherapeutics
Education
Pathology & Histology
Functional Service Provider (FSPx)
Education
Nonclinical
Early Phase Development
IND & CTA Enabling Studies
Nonclinical Locations
Ann Arbor
Harrogate
Madison
Shanghai
San Carlos
SEND 3.1
Educational Resources
Peri-approval & commercialization
Commercialization
Evidence generation
Field services
Market access consulting
Economic modeling
Pricing
Value communication
Access: Australia & Asia-Pacific
Patient Access Solutions
Assistance programs
Clinical services
Affordability
Pharmacy
Adherence
PV & Patient Safety
Aggregate reporting
Automation
Safety consulting
Pharmacovigilance (PV)
Safety Technology
Detection & risk management
Education
Phase IV
Data and Technology
Commercialization
Patient Access Programs
Access and Strategy
Evidence Generation
Value Communication
Patient Support Services
Patient Assistance Programs (PAP)
Field Services
Covance Market Access - Australia
Access and Strategy
Evidence Generation
Value Communication
Phase IV Solutions
Patient Safety and Pharmacovigilance Services
PV Services
Patient Safety Solutions Resource Center
Pharmacovigilance Automation
Biomarkers
Strategic Approach
Regulatory
Preclinical
Clinical
Post-Market
Crop
Locations
Physical chemistry
Active
Formulated
Human safety
In silico
In vitro
General
Genetic
DART
Inhalation
Environmental safety
Ecotoxicology
Aquatic
Terrestrial
Environmental fate & metabolism
In vitro
Plant
Animal
Research models
Livestock
Dermal absorption
Radiosynthesis
Environmental Fate
Field trials
Residue analysis
Endocrine disruptors (ED)
ED regulatory support
ED global testing
Regulation & compliance
Biocides
Regulations
EU regulation
Authorization
Biopesticides
Labeling
Crop chemicals
Risk assessment
Innovation
Innovation
Chemical Testing
Locations
Physical Chemistry
Human Safety
In Silico
In Vitro Safety
General Tox
Genetic
Inhalation
DART
Environmental Safety
Ecotoxicology
Aquatic
Terrestrial
Fate & Metabolism
Environmental Fate
Animal Metabolism
Radiosynthesis
Endocrine Disruptors
ED Global Testing
Regulatory Consultancy
Classification & Labeling
Registration
Global Regulations
EU REACH
Brexit
Only Representative
UK REACH
U.S. TSCA
Non-REACH
K-REACH
Brexit
Only Representative
Approaches & Innovation
CoRAP
Locations
Greenfield
Huntingdon
Shardlow
Scientific spotlights
OECD 229
OECD 231
Research Models
MarketPlace
Clients
Pharma Companies
Biopharmaceutical
Partner
Approach
Value
Transition
Contact
Investigators
Order a Kit
Become an Investigator
Accreditations and Certifications
Current Investigator Resources
Courier Numbers
Label: UPS Express Critical
Order: Dry Ice
Privacy Statement: Institution
Privacy Statement: Investigator
Privacy Statement: Study Staff
Videos: Packing & Shipping
Videos: Sample Collection
FAQs
TESTUPS
Participate in a Trial
Device / Diagnostics
Education Center
Life Science Investor Solutions
Articles & Research
Blog
Knowledge Library
KL Detail
KL Search Page Custom
Secure PDF Viewer
PDF Viewer
About
About Us
Animal Welfare
Why Animal Research
Impact on Results
Beliefs in Action
Corporate Responsibility
Relentless Collaborators
Insightful Partners
Contact
Unsubscribe
Unsubscribe Confirmation
Preference Center
Thank You
Thank You
Vaccine Development
Preclinical
Clinical Trial Connect
Trials & Recruitment
Clinical Testing & Labs
Commercialization
Medical Device
Product Testing
CEO Updates
Webinars
Design Better Studies
Xcellerate Protocol Design Tool
Xcellerate Patient Intelligence
Improve Study Recruitment
Xcellerate Recruitment Analysis & Forecasting
Xcellerate Site List Tool
Xcellerate Spatial Cluster Analysis
Reduce Study Risk
Xcellerate Risk Assessment & Categorization Tool
Xcellerate Risk & Issue Management
Xcellerate Risk Review
Gain Operational Insights
Xcellerate Action Alerts
Xcellerate CRA Dashboard
Xcellerate Study Dashboard
Xcellerate Portfolio Dashboard
Ensure Data Quality
Xcellerate Medical Review
Xcellerate Statistical Review
Xcellerate Data Review
Access Central Lab Information
Xcellerate Lab Sponsor Portal
Xcellerate LabLink+
Xcellerate Lab Investigator Portal
Empower Your Data
Xcellerate Clinical Data Warehouse
Xcellerate Operational Data Warehouse
Maximize Product Access
Xcellerate Patient Access Toolkit
Xcellerate Access Intelligence Dashboard (XAID)
Transform Patient Safety
Xcellerate Case Management
Xcellerate Safety Reporting